US equities |
AAPL $332.57 ▼-1.70% MU $859.80 ▲+3.14% NVDA $208.11 ▲+2.99% AMD $488.69 ▲+4.68% SNDK $1,127.44 ▲+4.87% ORCL $124.22 ▲+4.19% PLTR $170.06 ▼-4.65% SPCX $140.60 ▲+3.11%
FinancialContent

Bioventus Inc. - Class A Common Stock (NQ:BVS)

11.06 -2.09 (-15.89%)
Delayed Quote Updated: 10:12 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bioventus Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Bioventus Names Robert Claypoole as President and Chief Executive Officer
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin Growth 
From Bioventus, Inc.
Via GlobeNewswire
News headline image
MedTech Bioventus' Stabilization Sparks Analyst Confidence, Earns Upgrade And Price Target Boost ↗
Canaccord Genuity has upgraded Biomedical Devices and Services company Bioventus Inc (NASDAQ: BVS), highlighting greater insight into the progress of the turnaround and plans for future investment and... 
Via Benzinga
News headline image
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Earnings Preview: Bioventus ↗
 
Via Benzinga
News headline image
Bioventus Earnings Preview ↗
 
Via Benzinga
News headline image
Recap: Bioventus Q1 Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: Bioventus ↗
 
Via Benzinga
News headline image
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Present at the Cantor Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus And 3 Other Stocks Under $5 Insiders Are Buying ↗
The Dow Jones closed lower by 175 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Over $1M Bet On Bioventus? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
News headline image
Barnwell Industries And 3 Other Stocks Under $3 Insiders Are Aggressively Buying ↗
The Dow Jones closed higher by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
$25M Bet On This Consumer Cyclical Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by over 250 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Over $2.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed lower by over 200 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
News headline image
Bioventus Completes Divestiture of its Wound Business
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Reports First Quarter Financial Results
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Announces Divestiture of its Wound Business
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Bioventus Inc. (NASDAQ:BVS) Long Term Investor Notice: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 04/25/2023 -- An investigation was announced for long-term investors in shares of Bioventus Inc. (NASDAQ:BVS) concerning potential breaches of fiduciary duties by certain... 
Via SBWire
News headline image
Bioventus Announces CEO Leadership Change
From Bioventus, Inc.
Via GlobeNewswire
News headline image
Last Day Of Q1 ↗
Wall Street bonuses fell 26% last year. This was the biggest drop since 2008. Wall Street is estimated to be responsible for 16% of all economic activity in NYC. Wild nights out for ibankers slowing... 
Via Benzinga
News headline image
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >